+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

From
From
From
From
From
From
From
From
From
From
Antibody Drug Conjugate - Competitive Landscape, 2026 - Product Thumbnail Image

Antibody Drug Conjugate - Competitive Landscape, 2026

  • Report
  • April 2026
  • 280 Pages
  • Global
From
From
From
From
From
HER2 Positive Gastric Cancer Pipeline Analysis Report 2026 - Product Thumbnail Image

HER2 Positive Gastric Cancer Pipeline Analysis Report 2026

  • Report
  • May 2026
  • 150 Pages
  • Global
From
Liver Cancer Drug Pipeline Analysis Report 2026 - Product Thumbnail Image

Liver Cancer Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • May 2026
  • 150 Pages
  • Global
From
TCR Therapy Drug Pipeline Analysis Report 2026 - Product Thumbnail Image

TCR Therapy Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • May 2026
  • 150 Pages
  • Global
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more